Oral composition, and method for suppressing bitterness derived from ergothioneine and off-flavor derived from glucosamine compound

MYPI2025000472A0Undetermined Publication Date: 2024-01-19SUNTORY HLDG LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2025000472
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-07-19
Filing Date
2023-07-12
Publication Date
2024-01-19

AI Technical Summary

Technical Problem

Ergothioneine and glucosamine compounds exhibit bitter and off-tastes that hinder their incorporation into oral compositions, making them less palatable and difficult to consume continuously.

Method used

Combining ergothioneine or its salt with a glucosamine compound in a specific weight ratio of 0.2 to 150, effectively suppressing the bitter taste of ergothioneine and the off-taste of glucosamine, including salty, sweet, and astringent flavors, to enhance the palatability of oral compositions.

Benefits of technology

The combination significantly reduces the bitterness and off-taste, making it easier to continuously ingest ergothioneine and glucosamine compounds, thereby improving the taste experience and usability of these compounds in food, cosmetic, and pharmaceutical products.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention aims to provide an oral composition containing ergothioneine or a salt thereof and a glucosamine-class compound, in which the bitterness derived from the ergothioneine or a salt thereof and the off-taste derived from the glucosamine-class compound are suppressed. The present invention relates to an oral composition containing a component (A) and a component (B) defined as follows: (A) ergothioneine or a salt thereof; and (B) glucosamine-class compound, wherein a (B) / (A) weight ratio of the component (B) in terms of glucosamine to the component (A) in terms of ergothioneine is 0.2 to 150.
Need to check novelty before this filing date? Find Prior Art

Description

Oral composition and method for suppressing bitterness derived from ergothioneine and off-taste derived from glucosamine-related compounds

[0001] The present invention relates to an oral composition containing ergothioneine or a salt thereof and a glucosamine-related compound, and also to a method for suppressing the bitterness derived from ergothioneine and the off-taste derived from a glucosamine-related compound.

[0002] Ergothioneine is a hydrophilic sulfur-containing amino acid known to have various physiological activities, including antioxidant activity. Regarding the physiological activities of ergothioneine, for example, Patent Document 1 reports that it has the effect of activating immune responses and promoting cytokine production. Due to its diverse physiological activities, ergothioneine has recently attracted attention for use in foods, cosmetics, and pharmaceuticals.

[0003] Glucosamine is an amino sugar in which the hydroxyl group at the second position of glucose is replaced with an amino group. Glucosamine is a component of cartilage, a tissue that absorbs shock in joints, and is used in health foods to improve symptoms such as osteoarthritis.

[0004] Japanese Patent Application Laid-Open No. 2017-218431

[0005] As described above, ergothioneine has useful physiological activities, and therefore foods such as supplements containing ergothioneine or its salts are useful for maintaining or improving health. However, ergothioneine or its salts have a unique flavor, particularly a stinging bitterness (bitterness), which leaves room for improvement when formulated into oral compositions. In addition, glucosamine has a unique off-taste, specifically a salty taste, a sweet taste that lingers on the tongue, and a bitter taste, which can cause problems when incorporated into oral compositions.

[0006] An object of the present invention is to provide an oral composition containing ergothioneine or a salt thereof and a glucosamine-related compound, in which the bitterness derived from ergothioneine or a salt thereof and the off-taste derived from the glucosamine-related compound are suppressed. Another object of the present invention is to provide a method for suppressing the bitterness derived from ergothioneine or a salt thereof and the off-taste derived from the glucosamine-related compound.

[0007] As a result of intensive research conducted by the inventors to solve the above-mentioned problems, they discovered that by combining ergothioneine or a salt thereof with a glucosamine-related compound in a specific ratio, it is possible to suppress the bitterness derived from ergothioneine or a salt thereof and the off-tastes derived from glucosamine-related compounds (salty taste, sweetness that lingers on the tongue, and characteristic off-tastes accompanied by acridity).

[0008] The present invention includes the following compositions, etc. [1] An oral composition containing the following components (A) and (B): (A) ergothioneine or a salt thereof, and (B) a glucosamine-related compound, wherein the weight ratio ((B) / (A)) of component (B) (converted to glucosamine) to component (A) (converted to ergothioneine) is 0.2 to 150. [2] The composition according to [1], wherein the glucosamine-related compound is at least one selected from the group consisting of glucosamine, its derivatives, and salts thereof. [3] The composition according to [1] or [2], wherein the glucosamine derivative is a compound in which the hydrogen atom of at least one hydroxyl group and / or the hydrogen atom of the amino group of glucosamine is substituted with an acyl group and / or alkyl group having 1 to 10 carbon atoms. [4] The composition according to any of [1] to [3], which is a food or drink. [5] A method for suppressing the bitterness derived from ergothioneine or a salt thereof and the off-taste derived from a glucosamine-related compound in an oral composition containing the following components (A) and (B): (A) ergothioneine or a salt thereof, and (B) a glucosamine-related compound, by adjusting the weight ratio ((B) / (A)) of component (B) (converted to glucosamine) to component (A) (converted to ergothioneine) to 0.2 to 150.

[0009] According to the present invention, an oral composition containing ergothioneine or a salt thereof and a glucosamine-related compound can be provided, in which the bitterness derived from ergothioneine or a salt thereof and the off-taste derived from the glucosamine-related compound are suppressed. Furthermore, according to the present invention, a method for suppressing the bitterness derived from ergothioneine or a salt thereof and the off-taste derived from the glucosamine-related compound can be provided.

[0010] The oral composition of the present invention contains (A) ergothioneine or a salt thereof and (B) a glucosamine-related compound, and the weight ratio ((B) / (A)) of component (B) (converted to glucosamine) to component (A) (converted to ergothioneine) is 0.2 to 150.

[0011] Ergothioneine is a type of sulfur-containing amino acid. In the present invention, ergothioneine is preferably L-ergothioneine. The salt of ergothioneine is not particularly limited as long as it is a pharmacologically acceptable salt or a salt acceptable for use in foods and beverages, and may be either an acid salt or a basic salt. Examples of acid salts include inorganic acid salts such as hydrochloride, sulfate, nitrate, and phosphate; and organic acid salts such as acetate, citrate, maleate, malate, oxalate, lactate, succinate, fumarate, and propionate. Examples of basic salts include alkali metal salts such as sodium salt and potassium salt; and alkaline earth metal salts such as calcium salt and magnesium salt.

[0012] Ergothioneine or a salt thereof is not limited in any way by its form, production method, etc. Ergothioneine or a salt thereof may be a chemically synthesized product, or may be extracted and purified from a natural product. L-ergothioneine is contained in large amounts in the Golden / Yellow Oyster Mushroom (scientific name: Pleurotus cornucopiae var. citrinopileatus), a mushroom of the Pleurotus genus in the family Pleurotus. L-ergothioneine is found in mushrooms such as white button mushrooms, crimini mushrooms, and portabella mushrooms (Agaricus bisporus), Grey Oyster Mushrooms (Pleurotus ostreatus), shiitake mushrooms (Lentinula edodes), Maitake mushrooms (Grifola frondosa), reishi mushrooms (Ganoderma lucidum), Yamabushitake mushrooms (Hericium erinaceus), Yanagimatsutake mushrooms (Agrocybe aegerita), and chanterelle mushrooms (Cantharella verruca). It is also contained in mushrooms such as mushrooms such as Pleurotus cibarius, porcini mushroom (scientific name: Boletus edulis), and morel mushroom (scientific name: Morchella esculenta). When obtaining L-ergothioneine from a natural product, it is preferably extracted from Pleurotus cornucopiae. Ergothioneine or a salt thereof can also be produced by microbial fermentation. Ergothioneine or a salt thereof may be isolated.

[0013] Glucosamine (2-amino-2-deoxy-D-glucose) is an amino sugar in which the hydroxyl group at the 2-position of glucose is replaced with an amino group. It is widely distributed in animal bodies as a component of mucopolysaccharides in cartilage, connective tissue, and other tissues. Glucosamine has a distinctive off-taste, including a salty taste, a sweet taste that lingers on the tongue, and a bitter taste. By including a glucosamine-related compound, the composition of the present invention reduces the bitterness inherent in ergothioneine or a salt thereof. Combining a glucosamine-related compound with ergothioneine or a salt thereof can also suppress the distinctive off-taste, including a salty taste, a sweet taste that lingers on the tongue, and a bitter taste, inherent in glucosamine-related compounds. This facilitates the continuous intake of ergothioneine or a salt thereof and a glucosamine-related compound.

[0014] In the present invention, the glucosamine compound is a general term for compounds including glucosamine, its derivatives, and salts thereof.

[0015] Glucosamine derivatives include, but are not limited to, compounds in which the hydroxyl group of glucosamine is esterified or etherified, and compounds in which the amino group is acylated. A preferred glucosamine derivative is a compound in which the hydrogen atom of at least one hydroxyl group and / or the hydrogen atom of the amino group of glucosamine is substituted with an acyl group and / or alkyl group having 1 to 10 carbon atoms. A more preferred glucosamine derivative is a compound in which the hydrogen atom of the amino group of glucosamine is substituted with an acyl group or alkyl group having 1 to 10 carbon atoms. The number of carbon atoms in the acyl group and / or alkyl group is preferably 1 to 8, more preferably 1 to 5, even more preferably 1 to 3, and particularly preferably 2. Specific examples of acyl groups include formyl, acetyl, propionyl, and benzoyl. More preferred glucosamine derivatives include N-acetylglucosamine and N-methyl-L-glucosamine, with N-acetylglucosamine being particularly preferred.

[0016] The salts of glucosamine or its derivatives are not particularly limited as long as they are pharmacologically acceptable salts or salts acceptable for use in foods and beverages, and examples thereof include inorganic acid salts such as hydrochloride, sulfate, nitrate, and phosphate; and organic acid salts such as acetate, citrate, maleate, malate, oxalate, lactate, succinate, fumarate, and propionate. Inorganic acid salts are preferred, and hydrochloride is more preferred.

[0017] The glucosamine-related compounds used in the present invention are not limited in any way by their form or production method, and may be commercially available products or those extracted and purified from natural products. For example, glucosamine can be obtained by hydrolyzing chitin contained in crustaceans such as crab, shrimp, and krill, or squid cartilage, with an acid or enzyme, followed by separation and purification.

[0018] In the composition of the present invention, the weight ratio of component (B) (converted to glucosamine) to component (A) (converted to ergothioneine) ((B) converted to glucosamine / (A) converted to ergothioneine) is 0.2 to 150. Ergothioneine or a salt thereof has a stinging bitter taste. Glucosamine-related compounds also have a distinctive off-taste. In a composition containing components (A) and (B), when the weight ratio of component (B) (converted to glucosamine) to component (A) (converted to ergothioneine) ((B) / (A)) is within the above range, the bitter taste derived from component (A) can be suppressed, and the off-taste derived from component (B) can also be suppressed. This facilitates continuous intake of ergothioneine or a salt thereof and a glucosamine-related compound. The weight ratio ((B) / (A)) is preferably 0.4 to 130, more preferably 0.5 to 120, even more preferably 1 to 100, particularly preferably 5 to 80, and most preferably 10 to 50.

[0019] The content of ergothioneine or a salt thereof in the composition of the present invention is not particularly limited and can be set depending on the form, etc. The content of ergothioneine or a salt thereof in the composition of the present invention, in terms of ergothioneine, is, for example, preferably 0.1 wt% or more, more preferably 0.5 wt% or more, even more preferably 0.6 wt% or more, even more preferably 0.8 wt% or more, particularly preferably 1 wt% or more, and preferably 50 wt% or less, more preferably 40 wt% or less, even more preferably 30 wt% or less, even more preferably 20 wt% or less, and particularly preferably 10 wt% or less. In one aspect, the content of ergothioneine or a salt thereof in the composition of the present invention, in terms of ergothioneine, is preferably 0.1 to 50 wt%, more preferably 0.5 to 40 wt%, more preferably 0.6 to 30 wt%, even more preferably 0.8 to 20 wt%, and particularly preferably 1 to 10 wt%. When the composition of the present invention contains two or more compounds as ergothioneine or a salt thereof, the content of ergothioneine or a salt thereof refers to the total content thereof. The ergothioneine content can be measured by high-performance liquid chromatography (HPLC). The amount of ergothioneine or a salt thereof converted into ergothioneine or a similar expression refers to the amount of ergothioneine in the case of ergothioneine. In the case of a salt of ergothioneine, it refers to the value obtained by multiplying the number of moles of the salt by the molecular weight of ergothioneine.

[0020] The content of the glucosamine-related compound in the composition of the present invention is not particularly limited and can be set depending on the form, etc. The content of the glucosamine-related compound in the composition of the present invention, calculated as glucosamine, is, for example, preferably 0.02% by weight or more, more preferably 0.1% by weight or more, even more preferably 1% by weight or more, even more preferably 5% by weight or more, even more preferably 10% by weight or more, even more preferably 20% by weight or more, particularly preferably 30% by weight or more, particularly preferably 40% by weight or more, and preferably 99% by weight or less, more preferably 95% by weight or less, even more preferably 90% by weight or less, even more preferably 80% by weight or less, even more preferably 70% by weight or less, and particularly preferably 60% by weight or less. In one embodiment, the content of the glucosamine-related compound in the composition of the present invention, in terms of glucosamine, is preferably 0.02 to 99 wt%, more preferably 0.1 to 99 wt%, even more preferably 1 to 99 wt%, even more preferably 5 to 95 wt%, even more preferably 10 to 90 wt%, even more preferably 20 to 80 wt%, particularly preferably 30 to 70 wt%, and particularly preferably 40 to 60 wt%. When two or more types of glucosamine-related compounds are contained, the above content refers to the total content of these compounds. The content of the glucosamine-related compound can be measured by HPLC. When the glucosamine-equivalent amount of a glucosamine-related compound or a similar expression is used, it refers to the amount of glucosamine. When a compound other than glucosamine is used, it refers to the value obtained by multiplying the number of moles of the compound by the molecular weight of glucosamine.

[0021] The composition of the present invention preferably contains 1 to 100 mg of ergothioneine or a salt thereof, more preferably 2 to 50 mg, even more preferably 5 to 25 mg, and particularly preferably 5 to 20 mg, in terms of ergothioneine per daily intake for an adult. The composition of the present invention preferably contains 10 to 5,000 mg of glucosamine-related compounds, more preferably 20 to 3,000 mg, and even more preferably 50 to 2,000 mg, in terms of glucosamine per daily intake for an adult.

[0022] Ergothioneine or its salts and glucosamine-related compounds are compounds that are contained in natural products and foods and beverages and are commonly consumed. Therefore, from the viewpoint of safety, it is believed that there are few problems with ingesting ergothioneine or its salts and glucosamine-related compounds daily. According to the present invention, it is possible to provide a composition that is highly safe and easy to ingest, with reduced bitterness derived from ergothioneine or its salts and reduced off-taste derived from glucosamine-related compounds.

[0023] As described above, ergothioneine or a salt thereof is known to exhibit a variety of physiological activities and health functions, such as antioxidant activity, brain function improving effect, anti-aging effect, eye disease improving effect, whitening effect, ultraviolet absorption effect, melanin production suppression effect, reactive oxygen species scavenging effect, elastase activity inhibitory effect, wrinkle formation suppression effect, skin sagging suppression effect, autophagy promotion effect, etc. Therefore, the composition of the present invention can be suitably used for antioxidant activity, brain function improving effect, anti-aging effect, eye disease, whitening effect, ultraviolet absorption effect, melanin production suppression, reactive oxygen species scavenging effect, elastase activity inhibition effect, wrinkle formation suppression effect, skin sagging suppression effect, autophagy promotion effect, etc.

[0024] Glucosamine compounds are known to exert health-promoting functions such as alleviating pain from osteoarthritis of the knee, osteoarthritis of the hip, etc. Since the composition of the present invention contains glucosamine compounds, it can also be used to obtain the above-mentioned effects exerted by these compounds.

[0025] The composition of the present invention can be used for either therapeutic (medical) or non-therapeutic (non-medical) purposes. Non-therapeutic is a concept that does not include medical procedures, i.e., human surgery, treatment, or diagnosis. The composition of the present invention can be in the form of a food or beverage, a pharmaceutical product, a quasi-drug, a feed, or the like. The composition of the present invention may be a material or a preparation to be incorporated into a food or beverage, a pharmaceutical product, a quasi-drug, a feed, or the like.

[0026] The composition of the present invention is an oral composition, and specific examples of oral compositions include foods and beverages, oral medicines, quasi-drugs, feeds, etc., preferably foods and beverages or oral medicines, more preferably foods and beverages.

[0027] The composition of the present invention may contain any additives and ingredients in addition to ergothioneine or a salt thereof and a glucosamine-related compound, as long as the effects of the present invention are not impaired. These additives and ingredients can be selected depending on the form of the composition, and those generally usable for oral compositions such as foods and beverages, pharmaceuticals, quasi-drugs, and feeds can be used. When the composition of the present invention is used as a food or beverage, pharmaceutical, quasi-drug, feed, or the like, the method for producing the composition is not particularly limited, and the composition can be produced by a general method. In one embodiment, the composition of the present invention may consist of ergothioneine or a salt thereof and a glucosamine-related compound. The form of the oral composition of the present invention is not particularly limited, and may be a solid (powder, granules, tablet, etc.), liquid, paste, etc.

[0028] For example, when the composition of the present invention is used as a food or beverage, various foods and beverages can be prepared by blending ergothioneine or a salt thereof and a glucosamine-related compound with ingredients that can be used in foods and beverages (e.g., food ingredients, food additives used as needed, etc.). The foods and beverages are not particularly limited, and examples thereof include general foods and beverages, health foods, health supplements, health drinks, functional foods, foods for specified health uses, and foods and beverages for patients. The health foods, health supplements, functional foods, foods for specified health uses, etc. can be used in various dosage forms, such as fine granules, tablets, granules, powders, capsules, chewable tablets, dry syrups, syrups, liquids, beverages, drinks, and liquid diets.

[0029] When the composition of the present invention is used as a pharmaceutical or quasi-drug, for example, ergothioneine or a salt thereof and a glucosamine-based compound can be combined with a pharmacologically acceptable carrier, additives added as needed, and the like to produce pharmaceuticals or quasi-drugs in various dosage forms. Such carriers, additives, and the like may be any pharmacologically acceptable carriers that can be used in pharmaceuticals or quasi-drugs, and examples thereof include one or more of excipients, binders, disintegrants, lubricants, antioxidants, colorants, and the like. Dosage forms for oral administration of pharmaceuticals or quasi-drugs include liquids, tablets, powders, fine granules, granules, sugar-coated tablets, capsules, suspensions, emulsions, chewable tablets, and the like.

[0030] When the composition of the present invention is used as feed, ergothioneine or a salt thereof and a glucosamine-related compound may be blended into the feed. Feed also includes feed additives. Examples of feed include livestock feed for cows, pigs, chickens, sheep, horses, etc.; small animal feed for rabbits, rats, mice, etc.; and pet food for dogs, cats, small birds, etc.

[0031] The subject to which the composition of the present invention is ingested or administered (also referred to as the administration subject) is not particularly limited, and is preferably a human or a non-human mammal, more preferably a human.

[0032] The present invention also encompasses the following method: A method for suppressing the bitterness derived from ergothioneine or a salt thereof and the off-taste derived from glucosamine-related compounds in an oral composition containing (A) ergothioneine or a salt thereof and (B) a glucosamine-related compound, by adjusting the weight ratio ((B) / (A)) of component (B) (converted to glucosamine) to component (A) (converted to ergothioneine) to 0.2 to 150. By adjusting the weight ratio ((B) / (A)) of component (B) (converted to glucosamine) to component (A) (converted to ergothioneine) to fall within the above range in the preparation of the oral composition, an oral composition can be obtained in which the bitterness derived from ergothioneine or a salt thereof and the off-taste derived from glucosamine-related compounds are suppressed.

[0033] The above method makes it possible to effectively suppress the bitterness derived from ergothioneine or a salt thereof and the off-taste derived from glucosamine-related compounds. By suppressing the bitterness derived from ergothioneine or a salt thereof and the off-taste derived from glucosamine-related compounds, the taste of the oral composition can be improved. In the above method, ergothioneine or a salt thereof, glucosamine-related compounds, and preferred embodiments thereof are the same as those in the oral composition of the present invention described above. The preferred range of the weight ratio ((B) / (A)) of component (B) (converted to glucosamine) to component (A) (converted to ergothioneine) is also the same as that in the oral composition of the present invention.

[0034] The bitter taste derived from ergothioneine or its salts and the off-taste derived from glucosamine-related compounds can be suppressed by the above-mentioned methods, but these unpleasant flavors may be suppressed in combination with other methods, such as a method of adding a sweetener or a flavoring agent to a component having such an unpleasant flavor to prepare a formulation, a method of coating the component with a sugar coating to prepare a formulation, or a method of encapsulating the component to prepare a formulation.

[0035] Glucosamine-related compounds are useful for suppressing the bitterness of ergothioneine or a salt thereof. The present invention also encompasses the use of (B) a glucosamine-related compound for suppressing the bitterness derived from (A) ergothioneine or a salt thereof. The amount of the glucosamine-related compound used is preferably such that the weight ratio ((B) / (A)) of (B) the glucosamine-related compound (converted to glucosamine) to (A) the ergothioneine or a salt thereof (converted to ergothioneine) is 0.2 or more, and more preferably such that the weight ratio is 0.2 to 150.

[0036] Ergothioneine or a salt thereof is useful for suppressing the off-taste of glucosamine-related compounds. The present invention also encompasses the use of (A) ergothioneine or a salt thereof for suppressing the off-taste derived from (B) glucosamine-related compounds. The amount of ergothioneine or a salt thereof used is preferably such that the weight ratio ((B) / (A)) of (A) ergothioneine or a salt thereof (in ergothioneine equivalent) to (B) glucosamine-related compounds (in glucosamine equivalent) is 0.2 or more, and more preferably such that the weight ratio is 0.2 to 150.

[0037] In this specification, a numerical range expressed by a lower limit and an upper limit, i.e., "lower limit to upper limit," includes the lower limit and the upper limit. For example, a range expressed by "1 to 2" means 1 or more and 2 or less, including 1 and 2. In this specification, the upper limit and the lower limit may be any combination of ranges.

[0038] The present invention will be described in more detail below with reference to examples, although the present invention is not limited to these examples.

[0039] The materials used in the following evaluation tests are as follows: (A) Ergothioneine: raw material containing 100% L-ergothioneine (B) Glucosamine hydrochloride: raw material containing 100% glucosamine hydrochloride

[0040] Example 1: Flavor Evaluation Test for Compositions Containing Ergothioneine and Glucosamine Hydrochloride Compositions containing ergothioneine and glucosamine hydrochloride were prepared, and three panelists skilled in sensory evaluation performed sensory evaluations. The amounts of (A) and (B) shown in Table 1 were mixed to prepare compositions of Samples 1 to 9 (compositions containing ergothioneine and glucosamine hydrochloride). The weight ratios of (B) / (A) ((B) / (A) in terms of glucosamine) in the compositions of Samples 1 to 9 are shown in Table 1. Each of the three panelists placed the entire amount of the prepared composition (for example, Sample 1, a total of 11 mg, consisting of 10 mg of ergothioneine and 1 mg of glucosamine hydrochloride) directly on their tongues, and evaluated the intensity of the bitterness derived from ergothioneine and the intensity of the off-taste derived from glucosamine hydrochloride according to the following criteria.

[0041] (A) Evaluation criteria for bitterness derived from ergothioneine The intensity of the bitterness of (A) ergothioneine alone (10 mg) was assigned 5 points (control 1) and 1 point for no bitterness derived from ergothioneine. Evaluations were made on a 5-point scale from 1 to 5 points (5 levels). The evaluations of three panelists were compiled and the average values ​​are shown in Table 1. 5 points: Strong bitterness derived from ergothioneine 4 points: Bitterness derived from ergothioneine 3 points: Slight bitterness derived from ergothioneine 2 points: Little bitterness derived from ergothioneine 1 point: No bitterness derived from ergothioneine

[0042] (B) Evaluation criteria for off-taste derived from glucosamine hydrochloride The intensity of the distinctive off-taste of the above (B) glucosamine hydrochloride alone (10 mg), accompanied by a salty taste, a sweet taste that lingers on the tongue, and a bitter taste, was assigned a score of 5 (Control 2), and 1 point was assigned to the absence of any off-taste derived from glucosamine hydrochloride. The evaluation was carried out on a 5-point scale from 1 to 5. The evaluations of three panelists were compiled, and the average values ​​are shown in Table 1. 5 points: Strong off-taste derived from glucosamine hydrochloride 4 points: Off-taste derived from glucosamine hydrochloride 3 points: Slight off-taste derived from glucosamine hydrochloride 2 points: Little off-taste derived from glucosamine hydrochloride 1 point: No off-taste derived from glucosamine hydrochloride

[0043] When the average scores for the evaluation of the bitterness derived from ergothioneine and the evaluation of the off-taste derived from glucosamine hydrochloride were both less than 4.0 points, it was evaluated that the bitterness derived from ergothioneine and the off-taste derived from glucosamine hydrochloride were suppressed.

[0044]

[0045] When glucosamine hydrochloride was not added, the stinging bitterness derived from ergothioneine was strongly felt (Control 1). On the other hand, when glucosamine hydrochloride alone was added, the off-taste derived from glucosamine hydrochloride was strongly felt (Control 2). In Samples 2 to 7 and Sample 9, in which the weight ratio ((B) / (A)) of (B) glucosamine hydrochloride (calculated as glucosamine) to (A) ergothioneine was in the range of 0.2 to 150, both the bitterness derived from ergothioneine and the off-taste derived from glucosamine hydrochloride were effectively alleviated.

Claims

1. An oral composition comprising the following components (A) and (B): (A) ergothioneine or a salt thereof, and (B) a glucosamine compound, wherein the weight ratio ((B) / (A)) of component (B) (converted to glucosamine) to component (A) (converted to ergothioneine) is 0.2 to 150.

2. The composition according to claim 1, wherein the glucosamine compound is at least one selected from the group consisting of glucosamine, its derivatives, and salts thereof.

3. The composition according to claim 2, wherein the glucosamine derivative is a compound in which the hydrogen atom of at least one hydroxyl group and / or the hydrogen atom of the amino group of glucosamine is substituted with an acyl group and / or alkyl group having 1 to 10 carbon atoms.

4. The composition according to any one of claims 1 to 3, which is a food or drink.

5. A method for suppressing the bitterness derived from ergothioneine or a salt thereof and the unpleasant taste derived from a glucosamine-related compound in an oral composition containing the following components (A) and (B): (A) ergothioneine or a salt thereof, and (B) a glucosamine-related compound, by adjusting the weight ratio ((B) / (A)) of component (B) (converted to glucosamine) to component (A) (converted to ergothioneine) to 0.2 to 150.